Complement pathway: Risk molecular pattern of cardiovascular diseases in patients with diabetic nephropathy
Abstract
Background: Diabetic nephropathy (DN) commonly occurs as a microvascular complication in individuals with diabetes mellitus (DM). The progression of renal dysfunction in DN patients leads to a marked rise in the risk of cardiovascular disease (CVD). At present, the effective treatment of DN and CVD necessitates the identification and management of their risk factors.
Methods: Patients diagnosed with DN from October 2022 to October 2023 were selected for cross-sectional study and divided into DN group (n = 58) and DN/CVD group (n = 40). Clinical data were collected for univariate analysis, and independent variables that were statistically significant were analyzed with multivariate Logistic regression to identify independent influencing factors of CVD in DN patients. A regression model was developed to examine the non-linear relationship between C1q, UA, CRP, and the risk of CVD. Receiver operating characteristic (ROC) curve was used to analyze the predictive efficacy of the indicators.
Results: UA and C1q, when elevated, were independent factors increasing the risk of CVD. A linear relationship existed between UA and C1q and the risk of CVD in DN patients, showing a correlation. C1q showed better predictive performance.
Conclusion: As UA and C1q levels rise, the risk of CVD in the DN group significantly increases. In DN patients, UA and C1q are associated with CVD development and progression, offering some supportive evaluation value for the patient's condition.
Copyright (c) 2025 JunFei Liu, XiaoPing Qian, TaoXia Wang, XiaoLi Liu, WeiGang Liu, LiJie Wang, HuiFang Zhang, Li Han, GuiYing Li, XiaoJuan Yu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.